Picture of Hikma Pharmaceuticals logo

HIK Hikma Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

REG - Hikma Pharmaceutical - Director/PDMR Shareholding

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230608:nRSH1186Ca&default-theme=true

RNS Number : 1186C  Hikma Pharmaceuticals Plc  08 June 2023

Notification and public disclosure of transactions by persons discharging
managerial responsibilities

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                                            Douglas Hurt
 2   Reason for the notification
 a)  Position/status                                                                 Non-Executive Director
 b)  Initial notification /Amendment                                                 Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                                            Hikma Pharmaceuticals PLC
 b)  LEI                                                                             549300BNS685UXH4JI75
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument and identification  Description: Ordinary shares of 10 pence each (Shares)
     code

                                                                                     ID Code: GB00B0LCW083
 b)  Nature of the transaction                                                       Market purchase of 1500 Ordinary Shares by Gillian Hurt, spouse of Douglas

                                                                               Hurt

 c)  Price(s) and volume(s)                                                          Price(s): £18.20

                                                                                     Volume(s):1500
 d)  Aggregated information

     -       Volume

     -       Price                                                                    1500

                                                                                      £18.20

     -       Total                                                                    £27,300
 e)  Date of the transaction                                                         6 June 2023
 f)  Place of the transaction                                                        London Stock Exchange (XLON)

 

Helen Middlemist, Deputy Company Secretary

+44 (0) 20 7399 2760

8 June 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGCGDLXDGDGXI

Recent news on Hikma Pharmaceuticals

See all news